Maren Hertweck-Dirnberger
Planegg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Journal: Blood
Published: April 03, 2023
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Journal: Haematologica
Published: August 19, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Journal: Haematologica
Published: November 13, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: January 23, 2020
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 15, 2018
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 08, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026